Genmab A/S (NASDAQ: GMAB) and Incyte Corporation (NASDAQ: INCY) announced a clinical trial collaboration on October 24, 2026, to evaluate Genmab’s investigational bispecific antibody petosemtamab alongside Incyte’s KRAS G12D inhibitor INCB161734 and standard chemotherapy in previously untreated metastatic colorectal cancer. The planned Phase 1/2 study will investigate whether combining EGFR-LGR5 targeting with direct KRAS inhibition can provide a new therapeutic approach for patients whose tumors carry the KRAS G12D mutation.
The agreement introduces a distinct development strategy for petosemtamab, which is already being investigated in Phase 3 colorectal cancer trials involving RAS and BRAF wild-type tumors. Expanding into KRAS-mutated disease is scientifically significant because activating mutations in the KRAS pathway are a well-established mechanism of resistance to conventional epidermal growth factor receptor-targeted antibodies.
The collaboration is therefore more consequential than simply adding another chemotherapy combination to an existing pipeline. It seeks to determine whether suppressing mutant KRAS activity can create an opportunity for additional therapeutic effects from an antibody acting on EGFR and LGR5, while chemotherapy addresses cancer cells through complementary cytotoxic mechanisms.
However, the October announcement establishes a clinical development agreement rather than a demonstrated therapeutic advance. The companies have not reported response rates, progression-free survival, overall survival or a completed safety assessment for the proposed three-component regimen. Its clinical potential remains dependent on the results of the planned study.
What will Genmab and Incyte evaluate in the new KRAS G12D colorectal cancer trial?
Under the agreement, Genmab will conduct a Phase 1/2 clinical study evaluating petosemtamab, INCB161734 and standard-of-care chemotherapy in the first-line treatment of KRAS G12D-mutated metastatic colorectal cancer. Incyte will provide clinical supplies of its investigational inhibitor and contribute to the study’s funding. The arrangement establishes operational responsibilities while allowing both companies to investigate the combined therapeutic potential of their respective assets.
The decision to investigate first-line treatment is important because patients entering this setting generally have not received systemic treatment for metastatic disease. The clinical objective is not to overcome resistance after several previous metastatic treatment regimens, but to determine whether molecularly targeted treatment can improve initial disease control when introduced alongside established chemotherapy.
The companies have not disclosed the planned enrolment, randomisation structure, chemotherapy backbone, dosing schedule or primary endpoints of the new study. They have also not provided a confirmed trial initiation date or a dedicated clinical trial registration identifier for this specific combination. Consequently, it would be premature to describe the planned programme as a randomised efficacy comparison against standard treatment.
An early development study involving two investigational targeted agents and chemotherapy will need to establish an acceptable combination dose and characterise potential overlapping toxicities. Subsequent assessment may include antitumor activity, response durability and pharmacodynamic evidence that the intended molecular pathways are being affected.
A particularly important design consideration will be whether the study can distinguish the contribution of each investigational component. A favourable response observed during combination therapy would not independently establish that both petosemtamab and INCB161734 are necessary unless the development programme includes appropriate comparative evidence.
Why does the KRAS G12D mutation create a difficult treatment challenge in metastatic colorectal cancer?
KRAS is a signalling protein involved in pathways that regulate cellular growth, proliferation and survival. Mutations affecting KRAS can produce persistent activation of downstream signalling, allowing cancer cells to maintain proliferative activity even when normal receptor-mediated regulatory mechanisms are interrupted. This makes KRAS alterations important both biologically and therapeutically.
The companies estimate that KRAS mutations occur in approximately 40% of colorectal cancers, with G12D representing the most common individual KRAS mutation. Incyte places the prevalence of KRAS G12D at approximately 15% of colorectal cancer cases. This represents a substantial molecularly defined patient population, although the number of patients eligible for a particular treatment would depend on disease stage, prior therapy, clinical characteristics and the eventual indication.
KRAS mutation status already influences colorectal cancer treatment decisions because conventional EGFR-targeted monoclonal antibodies are generally used in appropriately selected RAS wild-type disease. Activating KRAS mutations can maintain downstream signalling despite receptor inhibition, reducing the therapeutic effectiveness of traditional EGFR blockade.
That biological relationship is central to the new collaboration. Genmab is attempting to investigate petosemtamab in a population outside the RAS wild-type setting being studied in its current Phase 3 colorectal cancer programme. The addition of INCB161734 is intended to address an important molecular reason why EGFR-directed treatment has historically been less effective in KRAS-mutant disease.
However, direct inhibition of KRAS G12D does not automatically restore sensitivity to EGFR-targeted treatment. Tumor cells may retain alternative signalling mechanisms, develop adaptive resistance or exhibit biological differences affecting the combination’s activity. Establishing the proposed interaction will require laboratory and clinical evidence rather than relying solely on the complementary mechanisms.
How could petosemtamab’s EGFR-LGR5 mechanism complement direct KRAS G12D inhibition?
Petosemtamab, also known as GEN1158, is an investigational human immunoglobulin G1-based bispecific antibody designed to bind both epidermal growth factor receptor and leucine-rich repeat-containing G-protein-coupled receptor 5. EGFR participates in growth signalling, while LGR5 is associated with selected stem-like cell populations and biological processes involved in tumor maintenance.
Genmab has designed the antibody to inhibit EGFR-mediated signalling through a binding site that prevents ligand interaction. The company also reports that petosemtamab can promote EGFR degradation in cancer stem-like cells expressing both EGFR and LGR5. Its antibody structure is further engineered to support innate immune activity involving macrophages and natural killer cells.
These features provide several possible mechanisms of antitumor activity beyond the receptor-blocking function of conventional EGFR antibodies. In particular, the potential to affect EGFR-LGR5-expressing cancer cells could be relevant to populations associated with tumor persistence or treatment resistance. However, the clinical importance of these mechanisms in KRAS G12D-mutated colorectal cancer remains unproven.
INCB161734 acts through a different mechanism. It is an investigational, selective, orally administered small molecule designed to inhibit KRAS G12D in both its active and inactive conformational states. The approach is intended to suppress signalling driven by the mutant protein itself rather than relying exclusively on inhibition of upstream receptors.
The combination’s biological hypothesis is that directly inhibiting mutant KRAS could reduce persistent oncogenic signalling while petosemtamab acts on receptor-associated pathways and potentially engages additional immune mechanisms. Chemotherapy may provide further antitumor activity, creating a multi-mechanism treatment strategy.
Nevertheless, three complementary mechanisms do not necessarily produce additive or synergistic clinical benefit. Pharmacological interactions, adaptive signalling and treatment-related toxicity can influence the outcome. The planned Phase 1/2 study must establish whether the proposed rationale translates into a feasible treatment regimen with measurable activity.
How does the partnership differ from Genmab’s existing Phase 3 petosemtamab programme?
Genmab is already evaluating petosemtamab in two Phase 3 studies involving metastatic colorectal cancer with RAS and BRAF wild-type status. These studies investigate the antibody in combination with chemotherapy in first- and second-line treatment settings. Their molecular eligibility criteria distinguish them from the newly announced KRAS G12D programme.
The difference is fundamental because RAS wild-type and KRAS-mutant colorectal cancers cannot be treated as interchangeable biological populations. Results obtained in one group may support broader understanding of a medicine’s activity, but they do not automatically establish effectiveness in the other. The new collaboration therefore represents a separate clinical hypothesis requiring its own evidence.
One ongoing Phase 3 programme is evaluating petosemtamab plus chemotherapy against cetuximab plus chemotherapy in first-line left-sided, RAS and BRAF wild-type metastatic colorectal cancer. This provides a comparative development strategy in a population where EGFR-directed treatment already has an established clinical role.
By contrast, the KRAS G12D collaboration investigates whether adding a mutation-specific inhibitor can support use of petosemtamab in tumors traditionally less responsive to EGFR antibodies. The scientific question is not whether petosemtamab can simply replace another EGFR antibody, but whether the combined treatment can address a molecular resistance mechanism.
This distinction has consequences for trial design, patient selection and eventual commercial positioning. A positive result in RAS wild-type disease would not establish the new combination’s efficacy in KRAS G12D-mutated tumors, while the proposed study cannot be used to infer results from Genmab’s existing Phase 3 trials.
The partnership nonetheless demonstrates Genmab’s intention to develop petosemtamab across multiple molecularly defined colorectal cancer populations. Whether that strategy succeeds will depend on generating indication-specific evidence rather than assuming that activity in one tumor subtype supports broader use.
What does Incyte’s existing INCB161734 development programme reveal about clinical readiness?
INCB161734 is already under clinical investigation in KRAS G12D-mutated solid tumors, providing an existing development foundation for the proposed colorectal cancer study. Incyte is evaluating the molecule in an open-label Phase 1 programme involving monotherapy and combinations with established chemotherapy regimens. That research includes tumor types in which KRAS G12D is a relevant oncogenic driver.
The company has also advanced INCB161734 into the global Phase 3 DAWN-303 study in previously untreated pancreatic ductal adenocarcinoma carrying the KRAS G12D mutation. This trial evaluates the inhibitor alongside standard chemotherapy and represents a later-stage development programme in a different malignancy.
The progression into Phase 3 pancreatic cancer research indicates that Incyte has advanced the inhibitor beyond initial clinical exploration. However, the development stage of an asset does not establish efficacy across all tumor types, and pancreatic cancer results cannot be substituted for colorectal cancer evidence.
The biological context differs between malignancies even when they share an identical KRAS mutation. Co-occurring genetic alterations, tumor microenvironment characteristics, treatment history and signalling adaptations can all influence response to targeted therapy.
The new collaboration therefore adds a separate disease-specific development opportunity rather than extending an existing approval. Neither INCB161734 nor its proposed combination with petosemtamab has been authorised for metastatic colorectal cancer.
Why could resistance and treatment tolerability determine the success of the combination?
One of the principal challenges in targeted oncology is that suppression of a dominant growth pathway may trigger compensatory signalling or select for resistant tumor populations. KRAS-driven cancers can involve complex interactions among receptor pathways, downstream signalling proteins and tumor-specific genetic alterations. These mechanisms may limit the durability of treatment responses even when initial pathway inhibition is effective.
Combining EGFR-associated targeting with direct KRAS G12D inhibition may be intended to reduce opportunities for adaptive signalling. However, whether the combination suppresses clinically relevant resistance pathways will need to be demonstrated using molecular and clinical measurements. Changes in circulating tumor DNA, tumor response and progression patterns could provide useful information if incorporated into the trial.
Safety will be equally consequential. EGFR-directed treatments can be associated with dermatological and gastrointestinal adverse effects, while investigational KRAS inhibitors require careful assessment of their own organ-specific toxicity profiles. Chemotherapy introduces additional risks, including myelosuppression, gastrointestinal toxicity and treatment-related fatigue, depending on the selected regimen.
The adverse-event profile of the exact three-component combination has not been established. Investigators will need to determine whether the treatments can be administered together without unacceptable toxicity or dose modifications that undermine pharmacological activity.
Treatment burden may also become relevant because the regimen combines an antibody-based medicine, an oral targeted agent and chemotherapy. The resulting schedule could involve infusion appointments, ongoing oral dosing and laboratory monitoring. Its clinical value would need to justify the additional complexity compared with existing first-line treatment options.
What are the commercial and financial implications for Genmab and Incyte?
The collaboration gives Genmab an opportunity to investigate petosemtamab in a new molecularly selected colorectal cancer population while using an externally developed KRAS inhibitor. For Incyte, the arrangement allows INCB161734 to be evaluated in an additional tumor type and combination strategy without independently conducting the entire study.
Genmab will lead the Phase 1/2 programme, while Incyte will co-fund the research and provide clinical drug supply. The companies have not disclosed financial commitments, cost-sharing percentages, commercialisation rights arising from the study or any potential milestones connected with the collaboration.
These undisclosed terms prevent a reliable estimate of the agreement’s direct financial value. The arrangement should not be interpreted as a broad commercial licensing transaction or evidence that either company has secured a new revenue stream. Its immediate significance is the establishment of a research programme involving complementary investigational assets.
The development also comes amid substantial investor attention surrounding Genmab’s oncology pipeline. Genmab’s Nasdaq-listed American depositary shares closed at $43.79 on October 23, 2026, advancing approximately 9.5% during the session following major Phase 3 ovarian cancer results announced separately. The KRAS collaboration was announced on October 24, after the latest regular United States trading session, so the October 23 share-price increase cannot be attributed to this partnership.
Incyte shares closed at $115.71 on October 23, down approximately 1.0% for the session. Its broader oncology pipeline and commercial business are substantially more important to near-term valuation than an early-stage collaboration whose clinical outcomes and economics remain undetermined.
For both companies, the relevant investment consideration is whether the partnership can generate a differentiated clinical opportunity without introducing excessive development costs or compromising existing programme priorities. The potential market is meaningful, but addressable patient numbers should not be confused with achievable commercial revenue.
What will determine whether the KRAS G12D collaboration becomes a viable colorectal cancer treatment?
The first significant milestone will be confirmation of the study design and initiation of clinical enrolment. Investigators will need to establish the appropriate combination dosing, characterise treatment-related toxicities and determine whether the regimen produces meaningful antitumor activity in KRAS G12D-mutated metastatic colorectal cancer.
Subsequent evidence should clarify whether the combination provides benefits beyond those achievable with chemotherapy and whether the proposed EGFR-LGR5 and KRAS mechanisms contribute meaningfully to treatment response. Response durability, progression-free survival and molecular evidence of pathway inhibition will be important in determining whether larger randomised studies are justified.
A successful early-stage signal would still require confirmatory development before regulatory approval could be considered. No clinical data currently establish that the three-component regimen improves survival, overcomes EGFR resistance or provides a new standard of care.
The October 2026 partnership therefore marks an expansion of targeted oncology research into a molecularly challenging patient population. Its significance lies in testing whether direct KRAS G12D inhibition can support a broader therapeutic role for petosemtamab, an approach whose clinical value remains to be determined through the planned Phase 1/2 study.
